Uncategorized
ThromboGenics enters into exclusive licensing agreement with Galapagos
ThromboGenics has signed an exclusive licensing agreement with Galapagos to develop and commercialize integrin antagonists to treat diabetic eye disease, according to a press release. ThromboGenics will pay a 1 million upfront technology transfer payment to Galapagos, and Galapagos will receive development and commercial milestone payments and royalties based on any future net sales from products that originated from Galapagos’ library of integrin antagonists.